T1	Participants 105 129	resectable rectal cancer
T2	Participants 488 588	Twelve radiotherapy departments with more than 10% of the evaluable patients recruited in the trial,
T3	Participants 321 486	radiotherapy institutions participating in the framework of a multicentre phase-III European Organization for Research and Treatment of Cancer (EORTC) clinical trial
T4	Participants 695 910	five full patient records with the chemotherapy charts, surgical and pathology reports, radiation treatment charts, treatment planning calculations, computed tomography (CT) scans, portal images and follow-up charts
T5	Participants 1319 1462	In general, the patients were eligible, documentation of clinical data was fair to good and there were no systematic major protocol deviations.
